<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04555291</url>
  </required_header>
  <id_info>
    <org_study_id>19-PP-13</org_study_id>
    <nct_id>NCT04555291</nct_id>
  </id_info>
  <brief_title>Analgesic Effect of the QLB-3 for Patients Undergoing a Total Hip Surgery</brief_title>
  <acronym>QLB-3</acronym>
  <official_title>Analgesic Efficiency of the Type 3 Quadratum Lumborum Block in Patients Undergoing Total Hip Arthroplasty : a Randomized Double Blinded Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Total hip arthroplasty (THA) is one of the main elective orthopedic surgery. Recent studies&#xD;
      have proven that patients undergoing an elective THA who are part of a fast track surgery&#xD;
      program including an opioid free anesthesia (OFA) presented a decrease of mortality and a&#xD;
      reduced in-hospital length of stay. Based on the anatomical knowledges, the Quadratus&#xD;
      Lumborum Block seems to be an interesting locoregional technique for patients undergoing THA.&#xD;
      So far, there is no recommanded locoregional aesthesia in this indication. The investigators&#xD;
      hypothezised that QLB would give an efficient analgesia in the 24h following a THA.&#xD;
&#xD;
      Therefor, the study performed a prospective, randomized, double blind trial in the Nice&#xD;
      Universitary hospital of Pasteur 2 and in Arnault Tzanck Institute among all patients who&#xD;
      underwent THA, comparing a QLB using ropivacaïne 2mg/ml 20ml vs isotonic saline solution 20&#xD;
      ml.The main end-point is the decrease opiod consumption in the 24h following THA.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Opoïd consumption</measure>
    <time_frame>At 24 Hours</time_frame>
    <description>The main end point of this study is the decrease of opiod consumption in the 24h following THA.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>morphine equivalent dose</measure>
    <time_frame>At 48 Hours</time_frame>
    <description>following surgery at rest and in motion</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Total Hip Arthroplasty</condition>
  <arm_group>
    <arm_group_label>Drug Ropivacaïne 2 mg/ml</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of ropivacaïne 2 mg/ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NACL</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of NACL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine injection</intervention_name>
    <description>Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of ropivacaïne 2 mg/ml</description>
    <arm_group_label>Drug Ropivacaïne 2 mg/ml</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NACL</intervention_name>
    <description>Realization of the quadratum lumborum block type 3, ultrasounds' guided by the injection of 20 ml of NACL</description>
    <arm_group_label>NACL</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        • All adult patients with unilateral programmed total hip prosthesis surgery are included&#xD;
        in the absence of inclusion criteria.&#xD;
&#xD;
          -  Obligation for all patients to be affiliated with social security&#xD;
&#xD;
          -  Patient Informed Consent Signature&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  chronic opiod consumption&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  mental disorder that prevents the usage of the numeric analog scale&#xD;
&#xD;
          -  Contra indications of the realization of QLB&#xD;
&#xD;
               -  Local infection&#xD;
&#xD;
               -  Allergic to the local anesthesia&#xD;
&#xD;
               -  Hemostasis disorder&#xD;
&#xD;
               -  Incapacity of giving the consent : individuals under guardianship by court order,&#xD;
                  or under judicial protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rozier Romain</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anesthésie Réanimation - CHU de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rozier Romain</last_name>
    <phone>+33492038580</phone>
    <email>rozier.r@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de nice - Anesthésie Réanimation</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Rozier Romain</last_name>
      <email>rozier.r@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>Rozier Romain</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Arnaut Tzanck</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06700</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Tran Laurie</last_name>
      <email>drlaurietran@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Tran Laurie</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>September 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 18, 2020</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

